ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fosse, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fosse, E.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1999;67:1000
© 1999 The Society of Thoracic Surgeons

Commentary

Erik Fosse, MD, PhDa

a The Interventional Centre, Rikshospitalet, 0027 Oslo, Norway

Invited commentary

Since heparin-treated cardiopulmonary bypass surfaces were introduced in the early 1980s, several studies demonstrated reduction in complement and neutrophil activation and in coagulation when heparin-treated systems were used. In several clinical trials the heparin-treated system allowed reduction in the systemic heparinization, indicating improved biocompatibility. However, studies of low-risk patients failed to . . . [Full Text of this Article]


Related Article

Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial
Marco Ranucci, Alessandro Mazzucco, Renzo Pessotto, Giovanni Grillone, Valter Casati, Lorenzo Porreca, Roberto Maugeri, Marco Meli, Paolo Magagna, Silvia Cirri, Pierpaolo Giomarelli, Roberto Lorusso, and Annette de Jong
Ann. Thorac. Surg. 1999 67: 994-1000. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.